Mergers & acquisitions
UCB has announced that it is acquiring Zogenix as part of plans to expand its reach into commercializing and developing treatments for rare diseases.
Funds are always flowing in the life science industry. Here’s where the money’s headed this week.
The SPAC announced it is merging with medical technology company ProKidney LP, in a deal that values the combined equity of the companies at $2.64 billion.
Based on the success of a joint immuno-oncology antibody collaboration program targeting CD96, GlaxoSmithKline and 23andMe have extended their 2018 collaboration for an additional year.
Evotec entered into a drug discovery collaboration for metabolic diseases with Eli Lilly, focusing on kidney disease and diabetes.
GlaxoSmithKline has declined all three of Unilever PLC’s offers to acquire its Consumer Healthcare business, saying that the proposal undervalued the division’s present and further worth.
Emergent BioSolutions, Vir Biotechnology and Thermo Fisher, come into 2022 with reports of new opportunities, new vaccines, and partnership expansions.
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
Bayer has transformed its pipeline by acquiring multiple cell and gene therapy companies, paving the way for life-saving and life-altering therapies for patients with different disease types.
Amgen will partner with Arrakis Therapeutics for an innovative collaboration to research and develop RNA degrader therapeutics.
PRESS RELEASES